CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Summary Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) mediated by epithelial to mesenchymal transition (EMT). We investigate cell surface proteins that could be targeted by antibody-based or adoptive cell therapy approaches and identify CD70 as being highly upregulated in EMT-associated resistance. Moreover, CD70 upregulation is an early event in the evolution of resistance and occurs in drug-tolerant persister cells (DTPCs). CD70 promotes cell survival and invasiveness, and stimulation of CD70 triggers signal transduction pathways known to be re-activated with acquired TKI resistance. Anti-CD70 antibody drug conjugates (ADCs) and CD70-targeting CAR T cell and CAR NK cells show potent activity against EGFR TKI resistant cells and DTPCs. These results identify CD70 as a therapeutic target for EGFR mutant tumors with acquired EGFR TKI resistance that merits clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citationActivation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationSequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Self-citationEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387
Self-citationWu, Y.-L., Zhang, L., Kim, D.-W., Liu, X., Lee, D. H., Yang, J. C.-H., Ahn, M.-J., Vansteenkiste, J. F., Su, W.-C., Felip, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7326 · Cited by 333
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294
Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
Self-citationNilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4307 · Cited by 146
Self-citationGlioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Chahlavi, A., Rayman, P., Richmond, A. L., Biswas, K., Zhang, R., Vogelbaum, M., Tannenbaum, C., Barnett, G., & Finke, J. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4395 · Cited by 141
Immune Escape for Renal Cell Carcinoma: CD70 Mediates Apoptosis in Lymphocytes
Diegmann, J., Junker, K., Loncarevic, I. F., Michel, S., Schimmel, B., & von Eagelinq, F. (2006) · Neoplasia · doi:10.1593/neo.06451 · Cited by 92
Research works printed but not linked: 51
- Chung, 2011, Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs, Lung Cancer, 73, 176, 10.1016/j.lungcan.2010.11.011 · DOI · Paper page
- Uramoto, 2010, Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma, Anticancer Res., 30, 2513
- Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238 · DOI · Paper page
- Pao, 2005, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions, J. Clin. Oncol., 23, 2556, 10.1200/JCO.2005.07.799 · DOI · Paper page
- Nishino, 2017, Osimertinib in EGFR T790M-positive lung cancer, N. Engl. J. Med., 376, 1992, 10.1056/NEJMc1703339 · DOI
- Ou, 2017, Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non-small cell lung cancer, J. Thorac. Oncol., 12, 145, 10.1016/j.jtho.2016.09.131 · DOI
- Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin. Cancer Res., 22, 4585, 10.1158/1078-0432.CCR-15-3101 · DOI · Paper page
- Negrao, 2018, Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.9052 · DOI
- Negrao, 2021, Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer, J. Immunother. Cancer, 9
- Mazieres, 2019, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann. Oncol., 30, 1321, 10.1093/annonc/mdz167 · DOI · Paper page
- Byers, 2013, An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin. Cancer Res., 19, 279, 10.1158/1078-0432.CCR-12-1558 · DOI · Paper page
- Nolte, 2009, Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology, Immunol. Rev., 229, 216, 10.1111/j.1600-065X.2009.00774.x · DOI · Paper page
- Craddock, 2013, Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia, Leukemia, 27, 1028, 10.1038/leu.2012.312 · DOI
- Bowman, 1994, The cloning of CD70 and its identification as the ligand for CD27, J. Immunol., 152, 1756, 10.4049/jimmunol.152.4.1756 · DOI
- Chen, 2014, Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, Nat. Commun., 5, 5241, 10.1038/ncomms6241 · DOI · Paper page
- Kashima, 2021, Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer, Cancer Res., 81, 4835, 10.1158/0008-5472.CAN-20-2811 · DOI
- Roper, 2020, Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer, Cell Rep. Med., 1
- Chua, 2021, Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities, Clin. Cancer Res., 27, 5939, 10.1158/1078-0432.CCR-20-4607 · DOI
- Aigner, 2007, The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity, Oncogene, 26, 6979, 10.1038/sj.onc.1210508 · DOI · Paper page
- Sánchez-Tilló, 2010, ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1, Oncogene, 29, 3490, 10.1038/onc.2010.102 · DOI · Paper page
- Shen, 2016, TGF-beta1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN, Biomed. Pharmacother., 77, 1, 10.1016/j.biopha.2015.10.018 · DOI
- Yang, 2014, TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma, Leukemia, 28, 1872, 10.1038/leu.2014.84 · DOI · Paper page
- Becker, 2019, CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC, Cancer Res., 79, 4439, 10.1158/0008-5472.CAN-19-0024 · DOI
- Riether, 2017, CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia, J. Exp. Med., 214, 359, 10.1084/jem.20152008 · DOI · Paper page
- Lu, 2005, Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs, J. Immunol., 174, 6212, 10.4049/jimmunol.174.10.6212 · DOI · Paper page
- Riether, 2020, Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents, Nat. Med., 26, 1459, 10.1038/s41591-020-0910-8 · DOI · Paper page
- Arens, 2004, Signaling through CD70 regulates B cell activation and IgG production, J. Immunol., 173, 3901, 10.4049/jimmunol.173.6.3901 · DOI
- García, 2004, Signalling via CD70, a member of the TNF family, regulates T cell functions, J. Leukoc. Biol., 76, 263, 10.1189/jlb.1003508 · DOI
- Tricker, 2015, Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer, Cancer Discov., 5, 960, 10.1158/2159-8290.CD-15-0063 · DOI · Paper page
- Law, 2006, Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates, Cancer Res., 66, 2328, 10.1158/0008-5472.CAN-05-2883 · DOI
- Pich, 2016, Melanoma-expressed CD70 is involved in invasion and metastasis, Br. J. Cancer, 114, 63, 10.1038/bjc.2015.412 · doi:10.1038/bjc.2015.412
- Ryan, 2010, Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75, Br. J. Cancer, 103, 676, 10.1038/sj.bjc.6605816 · DOI
- Liu, 2018, Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs, Breast Cancer, 25, 706, 10.1007/s12282-018-0880-6 · DOI
- Jacobs, 2015, Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer, Oncotarget, 6, 13462, 10.18632/oncotarget.3880 · DOI
- Loenen, 1992, The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis, Eur. J. Immunol., 22, 447, 10.1002/eji.1830220224 · DOI · Paper page
- Kato, 2007, Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells, Exp. Hematol., 35, 434, 10.1016/j.exphem.2006.10.018 · doi:10.1016/j.exphem.2006.10.018
- Hintzen, 1991, A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex, J. Immunol., 147, 29, 10.4049/jimmunol.147.1.29 · DOI
- Jacobs, 2015, CD70: an emerging target in cancer immunotherapy, Pharmacol. Ther., 155, 1, 10.1016/j.pharmthera.2015.07.007 · DOI · Paper page
- Silence, 2014, ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade, mAbs, 6, 523, 10.4161/mabs.27398 · DOI
- Wischhusen, 2002, Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma, Cancer Res., 62, 2592
- Wang, 2012, Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma, Cancer Res., 72, 6119, 10.1158/0008-5472.CAN-12-0588 · DOI · Paper page
- Fukuda, 2019, Epithelial-to-Mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status, Cancer Res., 79, 1658, 10.1158/0008-5472.CAN-18-2052 · DOI
- Győrffy, 2013, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer, PLoS One, 8, 10.1371/journal.pone.0082241 · DOI · Paper page
- Mak, 2016, A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition, Clin. Cancer Res., 22, 609, 10.1158/1078-0432.CCR-15-0876 · DOI · Paper page
- Tang, 2013, A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients, Clin. Cancer Res., 19, 1577, 10.1158/1078-0432.CCR-12-2321 · DOI · Paper page
- Edgar, 2002, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids Res., 30, 207, 10.1093/nar/30.1.207 · DOI · Paper page
- Byers, 2009, Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer, Clin. Cancer Res., 15, 6852, 10.1158/1078-0432.CCR-09-0767 · DOI · Paper page
- Nanjundan, 2010, Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence, J. Thorac. Oncol., 5, 1894, 10.1097/JTO.0b013e3181f2a266 · DOI · Paper page
- Arbiser, 1997, Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways, Proc. Natl. Acad. Sci. USA, 94, 861, 10.1073/pnas.94.3.861 · DOI · Paper page
- Dang, 2012, Soluble CD27 induces IgG production through activation of antigen-primed B cells, J. Intern. Med., 271, 282, 10.1111/j.1365-2796.2011.02444.x · DOI
- Lin, 2014, Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition, BMC Genom., 15, 1079, 10.1186/1471-2164-15-1079 · DOI
Cited by
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Exploring the therapeutic implications of emerging surface targets associated with the EMT phenotype, including Netrin-1 (67, 68) and CD70 (69), may prove promising in combination with KRAS inhibition.”
BackgroundSelf-citationTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Progressive plasticity during colorectal cancer metastasis
Moorman, A., Benitez, E. K., Cambuli, F., Jiang, Q., Mahmoud, A., Lumish, M., Hartner, S., Balkaran, S., Bermeo, J., Asawa, S., et al. (2025) · Nature · doi:10.1038/s41586-024-08150-0 · Cited by 229
Metadata
- Authors
- Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., Yu, X., Ren, X., Diao, L., Shen, L., Wang, Q., Zhang, M., Robichaux, J. P., Shi, C., Pfeil, A. N., Tran, H., Gibbons, D. L., Bock, J., Wang, J., Minna, J. D., Kobayashi, S. S., Le, X., & Heymach, J. V.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 41
- Issue
- 2
- Pages
- 340-355.e6
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4320487352
- Cited by
- 106
- References
- 24
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 377 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Cancer Institute (5 P50 CA070907, CA016672, 1R01CA190628, 1R01CA234183-01A1, 1R01CA240257, 1R01CA247975, 1R50CA265307)
- Cancer Prevention and Research Institute of Texas (RP120348, RP170002)
- Emerson Collective
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.